TPST
Tempest Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Aug 24, 2026, 00:00 UTC
Justin Trojanowski resigned as Principal Financial Officer and Principal Accounting Officer of Tempest Therapeutics, Inc., effective September 1, 2026, and Nicholas Rossettos was appointed Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, effective the same date.
Aug 13, 2026, 20:25 UTC
Tempest entered into a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003.
Source:Aug 13, 2026, 00:00 UTC
Tempest Therapeutics entered into an equity line of credit agreement on August 13, 2026, committing to sell up to $50.0 million of its unregistered common stock to an accredited investor, with an initial available amount of $25.0 million and an additional $25.0 million subject to conditions.
Jul 21, 2026, 11:00 UTC
Tempest Therapeutics announced a strategic partnership with Hebei Senlang Biotechnology to develop TPST-4003, a CD7-targeted in vivo CAR-T candidate.
Source:Jun 30, 2026, 00:00 UTC
Rani Therapeutics Holdings, Inc. appointed Nicholas M. Maestas as Chief Financial Officer, effective June 29, 2026.
Source:Jun 4, 2026, 00:00 UTC
Nicholas Maestas resigned as Chief Financial Officer of Tempest Therapeutics, Inc., effective June 5, 2026, and Justin Trojanowski was appointed Vice President, Finance, Principal Financial Officer and Corporate Secretary, effective the same date.
Jun 4, 2026, 00:00 UTC
John David Yee was appointed as a Class II Director of Tempest Therapeutics, Inc., effective June 5, 2026.
Jun 2, 2026, 00:00 UTC
Tempest Therapeutics entered into a warrant exercise and inducement agreement with an unnamed holder, resulting in the exercise of existing warrants for 1,172,414 shares at $1.73 per share, generating $2.0 million in gross proceeds, and the issuance of a new warrant for up to 2,344,828 shares.